Integrating clinical-molecular data to predict PARP inhibitors efficacy in advanced ovarian cancer patients after interval cytoreductive surgery
CRS is a prognostic factor in PARPi-treated population as a PARPi efficacy surrogate. Integrating HRD status, CRS, and KELIM allows patients risk stratification and tailored maintenance. These results should be considered hypothesis-generating.
Authors
- Aurore Carrot (ORCID: https://orcid.org/0000-0002-8835-2865)
- Giovanni Scambia (ORCID: https://orcid.org/0000-0002-9503-9041)
- Giancarlo Troncone (ORCID: https://orcid.org/0000-0003-1630-5805)
- Olivier Colomban (ORCID: https://orcid.org/0000-0003-1671-3470)
- Luca Mastrantoni (ORCID: https://orcid.org/0000-0003-1853-4927)
- Carolina Maria Sassu (ORCID: https://orcid.org/0000-0002-1702-5859)
- Gian Franco Zannoni (ORCID: https://orcid.org/0000-0002-4473-7560)
- Domenica Lorusso (ORCID: https://orcid.org/0000-0003-0981-0598)
- Filippo Maria Capomacchia (ORCID: https://orcid.org/0000-0002-5509-4193)
- Francesco Pepe (ORCID: https://orcid.org/0000-0002-2803-9586)
- Cláudia Marchetti (ORCID: https://orcid.org/0000-0001-7098-8956)
- Benoît You (ORCID: https://orcid.org/0000-0002-3177-8857)
- Adriana Ionelia Apostol (ORCID: https://orcid.org/0009-0008-4614-9261)
- Camilla Nero (ORCID: https://orcid.org/0000-0002-4442-4046)
- Raffaella Ergasti (ORCID: https://orcid.org/0000-0002-5066-1419)
- Diana Giannarelli (ORCID: https://orcid.org/0000-0002-6085-1195)
- Gianluca Russo (ORCID: https://orcid.org/0000-0003-2698-9470)
- Alessia Piermattei (ORCID: https://orcid.org/0000-0001-7164-4952)
- Umberto Malapelle
- Anna Fagotti
Institutions
- Université Claude Bernard Lyon 1 (FR)
- Università Cattolica del Sacro Cuore (IT)
- Lyon College (US)
- Agostino Gemelli University Polyclinic (IT)
- Hospices Civils de Lyon (FR)
- Associazione Italiana Di Oncologia Medica (IT)
- Centre de Recherche en Cancérologie de Lyon (FR)
- University of Naples Federico II (IT)
- HCL Technologies (India) (IN)
Publication Details
- Journal
- Gynecologic Oncology
- Published
- 2025-03-05
- DOI
- https://doi.org/10.1016/j.ygyno.2025.02.016
- Citations
- 1
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 1.05